Kikuye Koyano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kikuye Koyano has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Amir M. Ashique
NGM Biopharmaceuticals Inc., South San Francisco, California. 2
80 shared publications - Betty Li
NGM Biopharmaceuticals Inc., South San Francisco, California. 2
80 shared publications - Bin Fan
NGM Biopharmaceuticals Inc., South San Francisco, California. 2
80 shared publications - Carmence Ho
NGM Biopharmaceuticals Inc., South San Francisco, California. 2
80 shared publications - Daniel D. Kaplan
NGM Biopharmaceuticals Inc., South San Francisco, CA, USA
80 shared publications - Hung-I Harry Chen
NGM Biopharmaceuticals Inc., South San Francisco, California. 2
80 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
LAIR1 expression on circulating immune cells in normal healthy donors and patients diagnosed with solid cancers and undergoing checkpoint inhibition.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
LAIR1 expression on circulating immune cells in normal healthy donors and patients diagnosed with solid cancers and undergoing checkpoint inhibition.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
NGM438 binding to cell-expressed LAIR1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
NGM438 binding to cell-expressed LAIR1.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
Figure S8 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
Figure S8 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
Figure S5 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
Figure S5 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
Figure S4 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms
Figure S4 from ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms